Kissei Pharmaceutical
Update in progress4547.T (Tokyo)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Kissei Pharmaceutical Co., Ltd. develops, manufactures, and sells medicines mainly in Japan. Its portfolio includes Calogra for ulcerative colitis; Tabneos for microscopic polyangiitis; Minirin Melt OD; Corsuba IV syringe for chronic ITP; Beova for overactive bladder; and Darbepoetin Alfa BS for renal anemia. Its pipeline includes CG0070 for non-muscle-invasive bladder cancer, Linzagolix for fibroids and endometriosis, KDT-3594 for Parkinson’s, KSP-0243 for ulcerative colitis, and Difelikefalin for uremic pruritus. Founded 1946, based in Matsumoto.
Company score
- Sentiment
- 0.27
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.23
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.18
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketTokyo (JPX)
- LocationJapan
- CEOMr. Mutsuo Kanzawa
- Founded1946
- Employees1,786
- Websitewww.kissei.co.jp
Identifiers
- ISINJP3240600001